Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Senti Biosciences Inc (SNTI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.16-6.85%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SNTI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Effective capital allocation and managing financial obligations | Management aims to improve financial performance despite a net loss of $4.22M in Q1 2026. | Under Pressure | incurs new debt or obligations beyond current levels | Debt exchanged for equity vs no new debt target SNTI completed the exchange of Senior Secured Convertible Notes for common stock, eliminating the debt instrument. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth investment tied to developing its programs, not an established earnings compounder. The long-term thesis is currently intact, but management execution is volatile and the evidence of progress remains limited.
SNTI is valued at a 39.12% premium to peers, with the valuation relying on the possibility that its programs create future value. Model confidence is low, and the evidence points to expensive valuation rather than a broader combination of weak fundamentals and market turbulence being priced in.
Near-term results remain uncertain: revenue was very limited in the two reported quarters, while the operating loss widened from the first quarter to the second. Management has named advancing retained Regulator Dial programs, moving SENTI-202 toward pivotal development, and reducing cash burn as priorities, but the supplied financials show limited delivery and an elevated risk of a next-quarter earnings miss.
Over the next several quarters, the thesis depends on visible progress in the retained programs and SENTI-202, alongside better control of operating expenses. The sector backdrop is a tailwind for now, but weakening jobs data or weaker results from sector bellwethers could remove that support; stronger bellwether results could sustain it.
For the 1-3 year view, the thesis remains intact but is fragile on execution: SNTI needs to show program progress and manage cash burn, while its expensive valuation leaves substantial expectations attached to future potential. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management aims to improve financial performance despite a net loss of $4.22M in Q1 2026. |
| Intact |
| net loss exceeds $4.22M in FY26 |
Net income: $-12.75M FY2026-Q2; GAAP. Published target: net loss less than $3M in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-12,750,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Increase revenue from near zero | A primary condition in Senti Biosciences Inc's published investment case. The stated target is revenue >= $33M in FY26. | Intact | revenue falls below $10M in FY26 | Revenue: $17,000 FY2026-Q2; GAAP. Published target: revenue >= $33M in FY26. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 202617,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.95 → $-0.96 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.95 | $100,000 | 1 / 1 |
| 2026-07-25 | $-0.95 | $50,000 | 2 / 2 |
| 2026-07-26 | $-0.95 | $50,000 | 2 / 2 |
| 2026-07-27 | $-0.95 | $100,000 | 1 / 1 |
| 2026-07-28 | $-0.95 | $50,000 | 2 / 2 |
| 2026-07-29 | $-0.95 | $50,000 | 2 / 2 |
| 2026-07-30 | $-0.95 | $100,000 | 1 / 1 |
| 2026-07-31 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-01 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-02 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-03 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-04 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-05 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-06 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-08 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-09 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-10 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-12 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-13 | $-0.95 | $50,000 | 2 / 2 |
| 2026-08-14 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-15 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-16 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-17 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-18 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-19 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-20 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-21 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-22 | $-0.95 | $100,000 | 1 / 1 |
| 2026-08-23 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-24 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-25 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-26 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-27 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-28 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-29 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-30 | $-0.96 | $100,000 | 1 / 1 |
| 2026-08-31 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-01 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-02 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-03 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-04 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-05 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-06 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-07 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-08 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-09 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-10 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-11 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-12 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-13 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-14 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-15 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-16 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-17 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-18 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-19 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-20 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-21 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-22 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-23 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-24 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-25 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-26 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-27 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-28 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-29 | $-0.96 | $100,000 | 1 / 1 |
| 2026-09-30 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-01 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-02 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-03 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-04 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-05 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-06 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-07 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-08 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-09 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-10 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-11 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-12 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-13 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-14 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-15 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-16 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-17 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-18 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-19 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-20 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-21 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-22 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-23 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-24 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-25 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-26 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-27 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-28 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-29 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-30 | $-0.96 | $100,000 | 1 / 1 |
| 2026-10-31 | $-0.96 | $100,000 | 1 / 1 |
| 2026-11-01 | $-0.96 | $100,000 | 1 / 1 |
| 2026-11-02 | $-0.96 | $100,000 | 1 / 1 |
| 2026-11-03 | $-0.96 | $100,000 | 1 / 1 |
| 2026-11-04 | $-0.96 | $100,000 | 1 / 1 |
| 2026-11-05 | $-0.96 | $100,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.